A mitochondria-targeted peptide that won its first approval a year ago for an ultra-rare heart disease is now being pitched at something far broader: human ageing itself. In 2026 a team built around SS-31 (elamipretide) was named one of ten finalist awardees in the $101 million XPRIZE Healthspan competition, with a plan to test whether the peptide can improve muscle, cognitive and immune function in older adults. That makes this a good moment for an honest ss-31 research review — because the ageing data that got the compound this far is almost entirely from mice, and the most interesting finding in it is arguably a negative one.

If you're new to the compound, start with our SS-31 profile for the mechanism and trial history, then come back for the ageing angle.

What Is SS-31 (Elamipretide), and Why the Ageing Field Cares

SS-31 is a synthetic tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, a lipid that helps organise the respiratory chain. The theory is simple and appealing: stabilise cardiolipin, restore cristae architecture, and mitochondria produce ATP more efficiently with less electron leak. Because mitochondrial decline is one of the standard "hallmarks of ageing", a drug that reliably improves mitochondrial function is an obvious longevity candidate.

That theory earned SS-31 its first regulatory win. The US FDA granted accelerated approval on 19 September 2025 for Forzinity (elamipretide) to improve muscle strength in Barth syndrome patients weighing at least 30 kg — the first approved mitochondria-targeted therapeutic, and only after an earlier complete response letter. Accelerated approval is conditional: continued approval depends on a confirmatory trial, the design of which the sponsor has said it will present in 2026.

The XPRIZE Healthspan Bet: $1M, and a Trial Not Yet Run

The ageing story is newer. A team pairing Mighty Therapeutics — which per its own announcements now houses the Stealth BioTherapeutics elamipretide programme — with a University of Washington group led by mitochondrial physiologist David Marcinek was named a Milestone 2 Awardee in XPRIZE Healthspan, receiving $1 million and moving into the final phase alongside nine other teams.

Two things are worth reading carefully in that announcement. First, the award is described as premised on data from a pilot study of elamipretide in older adults — a press-release description of an unpublished dataset, not a peer-reviewed result you can currently interrogate. Second, the randomised, double-blind, placebo-controlled study of muscle, cognitive and immune function in older adults is something the team plans to design. It has not reported. Nothing about a competition milestone is evidence that the peptide improves healthspan in humans.

What the Ageing Evidence Actually Shows — Mostly in Mice

Function improved; the biological clocks didn't move

The most complete ageing dataset is a 2025 Aging Cell paper (Mitchell et al.) in which aged C57BL/6J mice received eight weeks of elamipretide. The functional results were positive: improvements in cardiac global longitudinal strain and ejection fraction, reduced frailty accumulation, and attenuated loss of skeletal muscle force across stimulation frequencies — an effect that was clearest in female mice.

The negative result is the one worth remembering. Despite those functional gains, the authors found no consistent effect on cardiac or skeletal muscle epigenetic or transcriptomic age, and in most cases no statistically significant change in individual gene expression. Pathway-level analysis did show upregulation of mitochondrial organisation and energy metabolism and downregulation of inflammatory processes.

The honest reading: SS-31 behaved like a functional performance drug in old animals, not like something that reset biological age. Anyone selling it as "epigenetic age reversal" is contradicted by the best-powered ageing study on the compound. This is an eight-week study in mice; it has not been replicated in humans.

A 2026 rat study: better bioenergetics, no better function

A January 2026 paper in IJMS tested elamipretide in a rodent model of heart failure with preserved ejection fraction. Myocardial mitochondrial respiration improved — and cardiac function and structure did not. Endothelium-dependent relaxation was unimproved and elastin-mediated vascular elasticity was unaffected. The authors' conclusion was blunt: improving bioenergetics alone may not be sufficient once disease is established, and mitochondrial targeting does not address the vascular abnormalities that limit function.

That dissociation — mitochondria measurably better, whole-organism outcome unchanged — is the central risk for every mitochondrial longevity thesis, SS-31 included.

The Human Track Record Is Mixed, and That Matters

The largest human test remains MMPOWER-3, a phase 3 trial in primary mitochondrial myopathy that randomised 218 participants and missed both primary endpoints: six-minute walk distance and the Primary Mitochondrial Myopathy Symptom Assessment total fatigue score. It was generally well tolerated, with mostly mild-to-moderate adverse events. A prespecified subgroup with nuclear DNA variants showed a six-minute-walk improvement while the mitochondrial DNA subgroup did not — a hypothesis-generating post hoc signal, not proof of benefit.

So the human ledger reads: one accelerated approval in an ultra-rare disease affecting roughly 150 people in the US, one failed phase 3 in a related muscle indication, ongoing work in dry AMD and other mitochondrial diseases, and an unpublished pilot in healthy older adults. That is a thin base on which to build a healthspan claim, and the XPRIZE finalist trial exists precisely because that base needs thickening.

SS-31 Australia: Is SS-31 Legal in Australia?

Elamipretide is not on the Australian Register of Therapeutic Goods. There is no TGA-approved SS-31 product, no approved Australian indication, and no PBS listing — the US Forzinity approval has no automatic effect here, and the TGA does not recognise FDA decisions. Any Australian access to an unapproved medicine would have to run through a doctor using the Special Access Scheme or Authorised Prescriber pathways, which is a clinical decision, not a consumer one.

Practically, that means the SS-31 you see marketed online in Australia is sold as a "research chemical" with no TGA evaluation of its identity, purity, sterility or dose. Advertising unapproved prescription-type substances to consumers is not permitted here, and product quality is unverified by any regulator. We don't cover sourcing, and this site doesn't sell anything — see our peptides library for how we assess each compound, or join the free updates list for trial readouts as they publish.

What Would Actually Change the Picture

Three concrete things to watch, in order of weight:

  1. The XPRIZE-linked randomised trial in older adults — if it runs and reports a placebo-controlled functional benefit, that's the first real healthspan evidence for the class.
  2. The Barth syndrome confirmatory trial — accelerated approval can be withdrawn; a confirmed clinical benefit would anchor the whole mechanism.
  3. Peer-reviewed publication of the older-adult pilot — until the data are public, a press-release mention of a pilot study is not something readers can weigh.

Until then, the fairest summary of ss-31 research in ageing is: a plausible mechanism, one approved ultra-rare indication, consistent mitochondrial biomarker effects, and a stubborn, repeated gap between those biomarkers and outcomes that matter.

FAQ

What is SS-31 (elamipretide) used for?

Its only approved use is in the United States, where FDA granted accelerated approval in September 2025 for Forzinity to improve muscle strength in Barth syndrome patients weighing at least 30 kg. All other uses — ageing, heart failure, eye disease — remain investigational.

Does SS-31 reverse biological age?

Not on the available evidence. In the 2025 Aging Cell mouse study, eight weeks of elamipretide improved cardiac and skeletal muscle function and reduced frailty but produced no detectable change in epigenetic or transcriptomic age.

Is SS-31 legal in Australia?

Elamipretide is not on the ARTG, so there is no approved SS-31 medicine in Australia. Access to an unapproved medicine would only be via a prescriber using pathways such as the Special Access Scheme; material sold online as a research chemical is not TGA-evaluated.

Has SS-31 failed any clinical trials?

Yes. The phase 3 MMPOWER-3 trial in primary mitochondrial myopathy randomised 218 people and missed both primary endpoints — six-minute walk distance and total fatigue score.

Sources

This article is information only, not medical advice. SS-31 (elamipretide) holds US accelerated approval for Barth syndrome only and is not registered on the ARTG in Australia; all ageing-related uses are investigational. retatrutide.net.au is independent and does not sell or supply any compound.